文献速递甲状腺疾病

中东地区分化型甲状腺癌中肿瘤大小与BRAF突变状态的预后影响

The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究比较了1709例连续手术的分化型甲状腺癌患者中,诊断时肿瘤大小与无事件生存(EFS)的关系,并按BRAF状态分组。结果显示,肿瘤>4 cm与多项不良临床病理特征相关,且肿瘤大小与BRAF突变呈负相关。无论BRAF突变状态如何,较大肿瘤均为EFS的独立预测因素。

要点

  • 肿瘤>4 cm与高龄、男性、双侧肿瘤、甲状腺外侵犯、脉管侵犯、晚期分期及持续/复发疾病相关。
  • 肿瘤大小与BRAF突变呈负相关。
  • 无论BRAF状态如何,肿瘤>4 cm均为EFS的独立预测因素。

核心结论

  • 在中东地区分化型甲状腺癌患者中,肿瘤大小是EFS的独立预测因素,无论BRAF突变状态如何。

研究设计与样本

  • 对1709例连续手术的分化型甲状腺癌患者进行的比较研究,按肿瘤大小(≤4 cm或>4 cm)和BRAF突变状态分为4组:组1(≤4 cm无BRAF突变)、组2(≤4 cm有BRAF突变)、组3(>4 cm无BRAF突变)、组4(>4 cm有BRAF突变)。
  • 采用log-rank检验和Cox比例风险模型比较EFS的预测因素。

主要发现

  • 肿瘤>4 cm与高龄、男性、双侧肿瘤、甲状腺外侵犯、脉管侵犯、晚期肿瘤分期及持续/复发疾病相关。
  • 肿瘤大小与BRAF突变呈负相关。
  • 单因素分析中,肿瘤>4 cm和BRAF突变均与EFS相关。
  • 亚组分析中,较大肿瘤是EFS的独立预测因素(组3 vs 组1),不受BRAF突变状态影响。
  • 在BRAF突变肿瘤中,较大肿瘤仍是EFS的独立预测因素(组4 vs 组2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Tumor size at diagnosis has been widely used as a major mortality risk factor in risk stratification of differentiated thyroid cancer (DTC). OBJECTIVE: The current study was designed to analyze whether tumor size at diagnosis is a major prognostic factor in Middle Eastern DTC. METHODS: We conducted a comparative study of the relationship between tumor size at diagnosis and event-free survival (EFS) with respect to BRAF status in 1709 consecutive patients treated surgically for DTC. Patients were divided into 4 groups according to the size of tumor and BRAF mutation status: Group 1 (≤4 cm without BRAF mutation), Group 2 (≤4 cm with BRAF mutation), Group 3 (>4 cm without BRAF mutation), and Group 4 (>4 cm with BRAF mutation). Predictors of EFS were compared using the log-rank test and Cox proportional hazards models. RESULTS: Tumor size >4 cm was associated with clinicopathologic characteristics, such as older age, male gender, bilateral tumors, extrathyroidal extension, lymphovascular invasion, advanced tumor stage, and persistent/recurrent disease. Tumor size was also inversely associated with BRAF mutation. Both tumor size (>4 cm) and BRAF mutation were associated with EFS on univariate analysis. On subgroup analysis, larger tumor size was an independent predictor of EFS (Group 3 vs Group 1), irrespective of BRAF mutation status. Also, within the BRAF mutant tumors, larger tumor size was still an independent predictor of EFS (Group 4 vs Group 2). CONCLUSION: Tumor size is an independent predictor of EFS in Middle Eastern patients with DTC, regardless of BRAF mutational status.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Parvathareddy SK, Siraj AK, Qadri Z, et al. The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39422185. doi:10.1210/clinem/dgae740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。